
13therapeutics Inc (AKA: Gene Targeted Delivery Inc~Targeted Gene Delivery Inc) Profile last edited on: 3/28/17
CAGE: 4FJ08
UEI: T5LFW55EF769
Business Identifier: Identify, characterize, and optimize anti-inflammatory peptide therapeutics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
4640 Sw Macadam Avenue Suite 200d
Portland, OR 97239
Portland, OR 97239
(503) 525-4887 |
info@13therapeutics.com |
www.13therapeutics.com |
Location: Single
Congr. District: 03
County: Multnomah
Congr. District: 03
County: Multnomah
Public Profile
Formerly known as Targeted Gene Delivery Inc, 13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses, fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases. Many of the companyâs peptides are capable of multiple methods of delivery, have shown serum stability, and have other desired features clinical therapeutics. Target conditions include the treatment of acute inflammatory diseases such as Acute Otitis Media (AOM), Systemic Inflammation, Meningitis, Traumatic Brain Injury (TBI), Uveitis and Ischemia. We are also evaluating peptides in chronic models for Lupus, Rheumatoid Arthritis (RA), Multiple Sclerosis, Atherosclerosis, Crohnâs Disease and Psoriasis, among others. Using our evolution-based methodology, we envision rapid development across several disease sta
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2013 | 2 | NIH | $3,745,316 | |
Project Title: Bacterial-Induced Sepsis: a New Treatment Strategy | ||||
2008 | 2 | NIH | $2,293,632 | |
Project Title: New Treatment for Inflammation in Middle Ear Infections | ||||
2001 | 1 | NIH | $99,840 | |
Project Title: New Therapy for Cystic Fibrosis DNA-Induced Inflammation | ||||
1997 | 1 | NIH | $99,687 | |
Project Title: Gene Delivery by a Cell Surface Dna Binding Protein |
Key People / Management
Thomas H Bruggere -- Chairman and CEO
Steven H Hefeneider -- President
Stephen E Kurtz
Sharon L McCoy -- Vice President of Product Development and Director of Research
Louise S Merkens
Steven H Hefeneider -- President
Stephen E Kurtz
Sharon L McCoy -- Vice President of Product Development and Director of Research
Louise S Merkens
Company News
There are no news available.